These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

866 related items for PubMed ID: 9166466

  • 1. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G, Barbareschi M, Boracchi P, Verderio P, Caffo O, Meli S, Dalla Palma P, Marubini E, Bevilacqua P.
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [Abstract] [Full Text] [Related]

  • 2. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P.
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [Abstract] [Full Text] [Related]

  • 3. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY, Gion M.
    Cancer J Sci Am; 1999 Feb; 5(2):101-11. PubMed ID: 10198732
    [Abstract] [Full Text] [Related]

  • 4. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients.
    Gasparini G, Fox SB, Verderio P, Bonoldi E, Bevilacqua P, Boracchi P, Dante S, Marubini E, Harris AL.
    Clin Cancer Res; 1996 Jul; 2(7):1191-8. PubMed ID: 9816287
    [Abstract] [Full Text] [Related]

  • 5. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ.
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [Abstract] [Full Text] [Related]

  • 6. Tumor angiogenesis in women with node-positive breast cancer.
    Folkman J.
    Cancer J Sci Am; 1995 May; 1(2):106-8. PubMed ID: 9166461
    [No Abstract] [Full Text] [Related]

  • 7. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC, Chen SC, Chang HK, Hsueh S, Tsai CS, Lo YF, Hwang TL, Chen MF.
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [Abstract] [Full Text] [Related]

  • 8. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M, MacGrogan G, Brouste V, Mathoulin-Pelissier S, Durand M, Mauriac L.
    Cancer; 2007 Jun 01; 109(11):2197-204. PubMed ID: 17450590
    [Abstract] [Full Text] [Related]

  • 9. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, Gelmon KA.
    Cancer; 2008 Apr 01; 112(7):1437-44. PubMed ID: 18286526
    [Abstract] [Full Text] [Related]

  • 10. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M, Graf E, Jonat W, Eiermann W, Geberth M, Albert US, Gademann G, Conrad B, Stahl K, von Minckwitz G, Schumacher M, German Adjuvant Breast Cancer Group.
    J Clin Oncol; 2005 Nov 01; 23(31):7842-8. PubMed ID: 16258087
    [Abstract] [Full Text] [Related]

  • 11. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

  • 12. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
    Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF, Austrian Breast and Colorectal Cancer Study Group.
    Clin Cancer Res; 2009 Sep 15; 15(18):5888-94. PubMed ID: 19723645
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
    Escobar PF, Patrick RJ, Rybicki LA, Hicks D, Weng DE, Crowe JP.
    Ann Surg Oncol; 2006 Jun 15; 13(6):783-7. PubMed ID: 16604475
    [Abstract] [Full Text] [Related]

  • 14. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.
    Acta Oncol; 2009 Jun 15; 48(4):514-21. PubMed ID: 19107621
    [Abstract] [Full Text] [Related]

  • 15. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin.
    Pohl G, Rudas M, Dietze O, Lax S, Markis E, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R, Filipits M.
    J Clin Oncol; 2003 Oct 01; 21(19):3594-600. PubMed ID: 14512390
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW, Osborne CK, Vaughn CB, Martino S.
    Cancer; 2003 Jan 01; 97(1):21-9. PubMed ID: 12491501
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
    Yang Q, Sakurai T, Yoshimura G, Suzuma T, Umemura T, Nakamura M, Nakamura Y, Mori I, Kakudo K.
    Oncol Rep; 2003 Jan 01; 10(1):121-5. PubMed ID: 12469156
    [Abstract] [Full Text] [Related]

  • 18. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
    Tubiana-Mathieu N, Lejeune C, Bonnier P, Genet D, Adjadj DJ, Berda JF, Muracciole X, Delaby F, Clavere P, Benyoub A, Rhein B, Juin B, Piana L.
    Anticancer Res; 2001 Jan 01; 21(4B):3061-7. PubMed ID: 11712811
    [Abstract] [Full Text] [Related]

  • 19. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, Paridaens R, European Organisation for Research and Treatment of Cancer Breast Group, Scottish Breast Cancer Trials Group.
    Eur J Cancer; 2007 Jan 01; 43(2):331-40. PubMed ID: 17134892
    [Abstract] [Full Text] [Related]

  • 20. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
    Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, Wolmark N.
    J Clin Oncol; 2004 Nov 01; 22(21):4247-54. PubMed ID: 15452182
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.